McIlrath & Eck’s Exact Sciences EXAS Stock Holding History

McIlrath & Eck’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-20	Closed	-$1.36K	–	910
2023 Q1	$1.36K	Buy	+20	New	+$1.29K	﹤0.01%	816

Other funds holding EXAS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

McIlrath & Eck's EXAS Position: Q2 2023 in Review

McIlrath & Eck sold out of Exact Sciences (EXAS) in Q2 2023, closing a stake of 20 shares — an estimated $1.36K sold.

McIlrath & Eck first reported a position in EXAS in Q1 2023 and held it in 1 quarter. The position peaked at $1.36K in Q1 2023. 653 funds tracked by Wall St. Rank hold EXAS as of Q2 2023.

McIlrath & Eck reported no remaining Exact Sciences position as of Q2 2023 after selling out during the quarter.
McIlrath & Eck sold 20 Exact Sciences shares in Q2 2023, an estimated $1.36K.
McIlrath & Eck first reported a position in Exact Sciences in Q1 2023 and held it in 1 quarter.
McIlrath & Eck's Exact Sciences position peaked at $1.36K in Q1 2023.
653 funds tracked by Wall St. Rank held Exact Sciences as of Q2 2023.

Based on McIlrath & Eck's 13F filing for Q2 2023, filed 7 Aug 2023.